Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): David J Sprenkeler , Marc A Vos Added: 3 years ago
The concept of post-extrasystolic potentiation (PESP), which describes the phenomenon of increased contractility of the beat following an extrasystole, has intrigued physiologists and clinicians for more than 120 years. Since its first description in 1885 by Oskar Langendorff,1 PESP has become a widely debated concept, not only for its fundamental basis but also because of the potential… View more

Heart Failure

Electrophysiology & Arrhythmia
Author(s): Alexander Steger , Daniel Sinnecker , Petra Barthel , et al Added: 3 years ago
In 1885, Oscar Langendorff was the first person to describe the increase in contractility (‘Pulsverstärkung‘) that follows an extrasystole.1Langendorff experimented with spontaneously beating isolated frog hearts. He recorded the heartbeats by using a lever that transferred the contractile movements of the heart to a rotating drum. Electrical stimulation resulted in premature contractions that… View more

Anticoagulation
Anisotropic Cardiac Conduction
Author(s): Irum D Kotadia , John Whitaker , Caroline H Roney , et al Added: 3 years ago

Electrophysiology & Arrhythmia
The S-ICD Post-Market Approval Study - Michael Gold
Author(s): Michael R Gold Added: 6 years ago
Michael Gold from Medical University of South Carolina, Charleston, SA, S-ICD Registry: Subcutaneous ICD (S-ICD) Post-market approval study. Filmed by Radcliffe Cardiology on-site at HRS 2017. View more

Electrophysiology & Arrhythmia
AFSymposium 24: EMERGE LAA Post-Approval: Amulet LAA Occluder in US
Author(s): Christopher R Ellis Added: 2 months ago
AF Symposium 2024 – In this interview, Dr Christopher R Ellis (Vanderbilt University Medical Center, US) joins us to discuss the early findings from the EMERGE LAA Post-Approval Study.The study investigated the early postapproval outcomes of the Amulet occluder device within the United States, using data from the Left Atrial Appendage Occlusion Registry.Questions:What is the background of this… View more

Electrophysiology & Arrhythmia
Author(s): Ethan R Ellis , Mark E Josephson Added: 3 years ago
Cardiomyopathies are heterogeneous heart muscle disorders with a wide range of aetiologies and clinical manifestations. They are often defined by their causes (i.e. hypertension, prior myocardial infarction, valvular heart disease), although current major society definitions describe cardiomyopathy as the presence of abnormal myocardial structure and/or function in the absence of underlying… View more

Heart Failure

Electrophysiology & Arrhythmia
Author(s): Paul Wang Added: 1 year ago
AHA 22: Dr Paul Wang (Cardiac Arrhythmia Service at Palo Alto, Stanford, CA, US) joins us remotely to discuss the findings of the ENHANCE-AF trial, originally presented at the American Heart Association's 2022 Scientific Sessions. ENHANCE AF aimed to evaluate whether a shared-decision-making pathway tool would reduce the risk of stroke as a result of atrial fibrillation when compared to standard… View more

Electrophysiology & Arrhythmia
AHA 22: NOVA: Botulinium Toxin Type A in Patients with Post-Operative Atrial Fibrillation
Author(s): Jonathan Piccini Added: 1 year ago
AHA 22 - Dr Jonathan Piccini(Duke University Medical Center, Durham, US) joins us to discuss the findings of the NOVA Phase II trial (NCT03779841). NOVA Phase II is a multicenter, randomized, dose-ranging study that aims to find the efficacy and safety of botulinum toxin type A (AGN-151607) (AbbVie)in preventing post-operative atrial fibrillation (POAF) in patients undergoing open-chest cardiac… View more

Vascular Disease and Surgery

Electrophysiology & Arrhythmia